報價延遲最少15分鐘:2026/04/16 00:35 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
10.82 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-4.53/-0.43
|
|
企業價值
576.65M
|
| 資產負債 |
|
每股賬面淨值
5.21
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
9.68M
|
|
每股收益
2.62
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases. |
